BioCentury
ARTICLE | Clinical News

Sound reports Phase Ib data for SPI-1005 in Meniere's disease

November 30, 2017 11:27 PM UTC

In October, Sound Pharmaceuticals Inc. (Seattle, Wash.) reported top-line data from a Phase Ib trial in 40 patients with Meniere’s disease showing that oral ebselen (SPI-1005) for 21 days improved low frequency hearing in 55% of patients vs. 10% for placebo (p<0.05). The therapy also improved word recognition, tinnitus loudness and vertigo severity vs. placebo. The selenium-based small molecule mimic of glutathione peroxidase (GPX) that activates nuclear factor (erythroid-derived 2)-like 2 (NFE2L2; NRF2) was well tolerated. Data were published in The Lancet...